InvestorsHub Logo
Followers 87
Posts 6641
Boards Moderated 1
Alias Born 09/18/2009

Re: Diego Rivas post# 42574

Thursday, 06/06/2024 3:43:47 PM

Thursday, June 06, 2024 3:43:47 PM

Post# of 42746
Diego, I think management may have secured a revenue stream through licensing fees from Gracell, Mayo Clinic, Novavax, Sanofi, our PREACH-M and aGvHD partners. and others TBA, that will pay the $44M to our unsecured creditors, and negate the reason to remain in bankruptcy. How management wants to capitalize on the recall of their loaned shares remains to be seen and is irrelevant to me. And there are a host of other indications, including asthma, arthritis, malaria, Long Covid, etc., that I think will far surpass anyone's expectations. The Do or Die bankruptcy hearing is scheduled next week, on the 13th. If I have overstated our potential, it's because you sincerely asked if I thought there was something that could move the stock price. But even a more limited version of our opportunities could prove sufficient to successfully exit our CH11 proceeding.

It just makes no sense to raise the subject of an expanded program to meet Milestone Events without Humanigen capitalizing on their share structure and offering some type of distribution to existing equity holders, chiefly the company.